GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Eliem Therapeutics
Eliem is a biotech company whose stock plummeted after the failure of key clinical trials. Its price chart is a dramatic story of the hopes surrounding its drugs and the subsequent crisis, a prime example of binary risks in biotech.
Share prices of companies in the market segment - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nervous system disorders, including pain and depression. We've categorized it under the "Neurology" category. The chart below reflects how investors assess the risks and prospects in this complex area.
Broad Market Index - GURU.Markets
Eliem Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Its scientific research makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Eliem shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
ELYM - Daily change in the company's share price Eliem Therapeutics
Eliem Therapeutics, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for neurological disorders.
Daily change in the price of a set of shares in a market segment - Neuro
Eliem Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with ELYM's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
Eliem Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Eliem Therapeutics
For Eliem Therapeutics, its year-over-year performance is a story of its search for a new path. Its market cap change over the past 12 months reflects its status as a cash-rich company seeking a new asset for acquisition or merger following the failure of its previous clinical programs in neurology.
Annual dynamics of market capitalization of the market segment - Neuro
Eliem, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Eliem Therapeutics, a biotech company plagued by research setbacks, tells the story of its struggle for survival. Its performance, compared to the market, reflects investors' confidence in the remaining drugs in its portfolio. It's a risky bet on the company's ability to recover.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Eliem Therapeutics
Eliem is a biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its key drugs are binary events for its stock.
Monthly dynamics of market capitalization of the market segment - Neuro
Eliem Therapeutics is a pharmaceutical company developing drugs for the treatment of neurological and psychiatric disorders. This is one of the most challenging areas for drug development. The dynamics of the biotech sector reflect these risks and hopes. Eliem's story is an attempt to find new approaches to treating chronic pain, depression, and anxiety in this complex scientific environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Eliem Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to understand how its scientific data and progress in neuroscience trials have impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on treating neurological disorders. Its weekly stock price is highly volatile, driven by news of clinical trial results.
Weekly dynamics of market capitalization of the market segment - Neuro
Eliem Therapeutics develops drugs to treat neurological disorders. This is one of the most complex areas in pharmaceuticals, where failures are common. The chart below shows whether Eliem's share price fluctuations are a reaction to news about its research or reflect the general hopes and disappointments of investors in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Eliem is an early-stage biotech company. Its shares are buoyed by anticipation of research results. The chart clearly demonstrates how its performance is driven by scientific news rather than general market trends, creating its own unique path.
Market capitalization of the company, segment and market as a whole
ELYM - Market capitalization of the company Eliem Therapeutics
The market capitalization of Eliem Therapeutics, a neuroscience-focused biotech, is a story of clinical trial failures. The sharp decline in its chart reflects the discontinuation of its leading drugs. The current low valuation suggests the company is essentially a cash cow in search of new assets.
ELYM - Share of the company's market capitalization Eliem Therapeutics within the market segment - Neuro
Eliem Therapeutics is a biotech company focused on diseases of the nervous system. Its market share in the pharmaceutical sector is negligible. The company's market capitalization is entirely dependent on clinical trial results and reflects investors' speculative expectations regarding its experimental drugs.
Market capitalization of the market segment - Neuro
The chart below shows the market capitalization of the neuroscience pharmaceuticals sector. Eliem Therapeutics is a company focused on treating chronic pain and depression. Its complex history, with clinical trial failures, is a prime example of the complexity and risks of developing brain drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Eliem Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Its market capitalization reflects the potential of its scientific research in this complex field. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
ELYM - Book value capitalization of the company Eliem Therapeutics
Eliem Therapeutics' book value represents the capital it retains to pursue new opportunities after discontinuing development of its core drugs. The chart tells the story of a biotech company that has essentially become a "cash box," with its book value representing a resource for a potential merger or acquisition.
ELYM - Share of the company's book capitalization Eliem Therapeutics within the market segment - Neuro
Eliem Therapeutics treats neurological disorders. The chart shows its share of actual R&D assets. These are its laboratories where new drugs are being developed to treat chronic pain and depression.
Market segment balance sheet capitalization - Neuro
Eliem Therapeutics is a biopharmaceutical company specializing in the treatment of neurological diseases. Their value is created in the lab. A book value chart will show their R&D base, but it won't reflect the potential value of their intellectual property and development pipeline.
Book value of all companies included in the broad market index - GURU.Markets
Eliem Therapeutics's core assets include laboratories and R&D centers for developing drugs for the treatment of chronic pain and depression. The chart shows how the company built its scientific and physical capital to address complex neurological problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Eliem Therapeutics
Eliem Therapeutics develops drugs for the treatment of neurological diseases. Its tangible assets are minimal. The chart is a visual representation of the biotech startup's journey. Its ups and downs will be driven not by balance sheet changes, but by news about the progress of clinical trials, which determine the company's future.
Market to book capitalization ratio in a market segment - Neuro
Eliem Therapeutics is a clinical-stage biotech developing drugs for the treatment of chronic pain and depression. Its valuation is entirely dependent on clinical trial results. The chart clearly shows how its market capitalization, based on expectations, compares to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Eliem Therapeutics is a neuroscience biotech. Its valuation is entirely dependent on the prospects of its clinical programs. This metric clearly illustrates that investors are investing not in current assets, but in the future potential of its drugs, creating a colossal gap between market value and book value.
Debts of the company, segment and market as a whole
ELYM - Company debts Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotech focused on treating neurological disorders. This chart reflects its financial challenges following clinical trial failures. The company was forced to reduce staff and reassess its strategy, managing its remaining capital to advance its remaining programs.
Market segment debts - Neuro
Eliem Therapeutics is a clinical-stage biotech company developing treatments for neurological disorders. This field of medicine is known for its high failure rates in clinical trials. This chart clearly illustrates the high financial risk borne by the company and its investors.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on neuroscience. This chart shows its financial structure. For a company whose drugs have not yet reached the market, any debt is a significant risk. Failure in clinical trials would make servicing it impossible.
Market segment debt to market segment book capitalization - Neuro
Eliem Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological disorders. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its clinical research and development in this complex area of medicine.
Debt to book value of all companies in the market
Eliem Therapeutics is a clinical-stage biotech company specializing in the treatment of nervous system diseases. Developing such drugs is a long and expensive process. This graph of total market debt shows how willing the financial system is to finance such long-term, high-risk scientific projects.
P/E of the company, segment and market as a whole
P/E - Eliem Therapeutics
Eliem Therapeutics is a biotech company developing drugs for neurological disorders. This chart reflects the risks and setbacks in this complex field. Its dynamics show investor reactions to clinical trial results, which can be both successful and unsuccessful.
P/E of the market segment - Neuro
Eliem Therapeutics is a clinical-stage biotech company developing drugs to treat neurological disorders such as chronic pain and depression. This chart shows the average valuation for the neuroscience sector, reflecting how investors assess the risks and potential of companies working in this complex field of medicine.
P/E of the market as a whole
Eliem Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological disorders. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Eliem Therapeutics
Eliem Therapeutics is a biotech company developing drugs to treat neuronal disorders such as chronic pain and depression. This chart reflects market expectations for the success of its clinical programs. Future profits depend on breakthroughs in the treatment of these complex and common diseases.
%20P%2FE%20Eliem%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Eliem-Therapeutics&v=1772678949566 "Chart of the company's future (projected) P/E Eliem Therapeutics")
Future (projected) P/E of the market segment - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neuronal disorders such as pain and depression. The chart reflects average profitability expectations for the biotech sector. ELYM's position relative to this benchmark reflects investors' bet on its scientific approach and the success of its clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772678949567 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Eliem Therapeutics is a clinical-stage biopharmaceutical company developing new treatments for neurological disorders such as depression, anxiety, and chronic pain. This chart of overall market expectations illustrates investor appetite for the risk associated with funding long and complex clinical trials in CNS diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772678949571 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neurological disorders. Its financial structure is driven by research and development expenses. Potential profitability depends entirely on the success of its drug candidates in the treatment of pain and depression.
Profit of companies in the market segment - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on developing new treatments for neurological and psychiatric disorders. This chart shows the total revenue in its sector, illustrating the level of investor confidence in the commercial potential of developments for the treatment of complex neurological conditions and depression, where there is a significant need for innovation.
Overall market profit
Eliem Therapeutics is a biotech company developing drugs for the treatment of neurological diseases. Its value is determined by the potential of its scientific developments and the results of clinical trials. The overall market situation, reflected in this chart, directly impacts its ability to raise capital to finance its operations.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotech company focused on developing treatments for neuronal disorders such as pain and depression. Future profits depend on the success of its R&D. This chart reflects analysts' speculative expectations regarding the potential of its drugs in this complex therapeutic area.
%20profit%20of%20the%20company%20Eliem%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Eliem-Therapeutics&v=1772678949628 "Graph of future (projected) profit of the company Eliem Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Eliem Therapeutics is a biotech company developing new treatments for neurological disorders such as pain and depression. Its future depends on successful clinical trials and scientific breakthroughs. This chart reflects profitability forecasts for the entire pharmaceutical sector, allowing us to assess Eliem's potential in this complex and important area of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772678949629 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Eliem Therapeutics is a biopharmaceutical company focused on treating neurological diseases. Like other clinical-stage companies in this sector, its prospects depend on research success rather than macroeconomic indicators. This earnings chart is largely irrelevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772678949631 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on neurological diseases. Its valuation, shown in this chart, is based not on current revenue but on the potential of its experimental drugs. Fluctuations in this valuation directly reflect news about the progress of clinical trials.
P/S market segment - Neuro
Eliem Therapeutics is a biopharmaceutical company developing treatments for neurological disorders such as pain and depression. Future revenue depends on the success of its clinical programs. This chart for the neuroscience sector compares investor expectations for Eliem's pipeline with those of other companies in this complex field.
P/S of the market as a whole
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on developing new treatments for neuronal disorders such as pain and depression. This market revenue valuation chart helps understand how investors assess the risks and potential rewards associated with drug development in one of the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotech company focused on developing new treatments for neuronal disorders such as pain and depression. This chart shows how the market perceives the future commercial potential of its drug candidates. It reflects investor expectations for clinical trial success.
%20P%2FS%20Eliem%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Eliem-Therapeutics&v=1772678949637 "The graph of the company's future (projected) P/S Eliem Therapeutics")
Future (projected) P/S of the market segment - Neuro
Eliem Therapeutics is a clinical-stage biotech company focused on developing novel treatments for neuronal disorders such as pain and depression. The company's valuation reflects investors' opinions on the potential of its research and development pipeline, representing a high-risk bet on success in complex clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772678949649 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Eliem Therapeutics is a clinical-stage biotech company working on the treatment of neurological disorders. Its prospects depend on the success of its research. In the context of the overall revenue projections shown in the chart, Eliem represents a venture investment in the future of neuroscience.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772678949651 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for neurological disorders. The company currently has no commercial products and, therefore, no sales revenue. Any revenue reflected in the chart is due to funding from partners.
Sales of companies in the market segment - Neuro
Eliem Therapeutics (ELYM) is a biotechnology company focused on developing new treatments for neurological disorders and pain. This metric reflects revenue in the neurological pharmaceutical segment. Eliem strives to develop treatments for patients suffering from debilitating conditions for which there is a critical shortage of effective and safe therapies.
Overall market sales
Eliem Therapeutics is a biotech company developing treatments for neurological disorders. Its market capitalization depends on progress in clinical programs. This overall economic activity profile influences investor risk appetite. During favorable periods, investors are more willing to invest in biotech companies with long-term development cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Eliem Therapeutics
Eliem Therapeutics is a biotech company developing new treatments for neuronal disorders such as chronic pain and depression. Its future revenue is entirely dependent on clinical trial results. This chart reflects analyst expectations, which are essentially an assessment of the scientific potential and commercial prospects of its neuroscience developments.
%20sales%20of%20the%20company%20Eliem%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Eliem-Therapeutics&v=1772678949675 "Schedule of future (projected) sales of the company Eliem Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on treating diseases of the nervous system. This forecast chart reflects the potential future revenue from their pipeline. This is an analyst's perspective on the commercial prospects of their approaches to treating neuropathic pain and depression.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772678949687 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Eliem Therapeutics is a clinical-stage biotech focused on nervous system disorders such as pain and depression. It targets huge markets with significant unmet needs. This chart reflects the overall investment landscape, but for Eliem, progress in clinical trials is key, as it could bring hope to millions of patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772678949701 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Eliem Therapeutics
Eliem Therapeutics is a biotech company focused on developing new treatments for neurological disorders such as chronic pain and depression. Its financial performance reflects significant investment in clinical trials. The chart shows its current profitability as an investment in solving complex problems affecting the central nervous system.
Market segment marginality - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for neurological disorders. This chart reflects its operating expenses. The dynamics of this metric are important for assessing how effectively the company manages its capital during the drug development process.
Market marginality as a whole
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for neurological disorders. Its future depends on successful trials and capital raising. This total return chart reflects the investment climate. A favorable economic environment facilitates raising funds for long-term R&D projects.
Employees in the company, segment and market as a whole
Number of employees in the company Eliem Therapeutics
Eliem Therapeutics is a biopharmaceutical company developing treatments for diseases associated with neuronal hyperexcitability, such as chronic pain and depression. This chart shows the size of its scientific and clinical teams, which are advancing its pipeline through complex clinical trials.
Share of the company's employees Eliem Therapeutics within the market segment - Neuro
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on diseases of the nervous system. Its core resource is its clinical trial team. This chart illustrates the scale of its investment in human capital to conduct research that could lead to new treatments for patients with chronic pain and depression.
Number of employees in the market segment - Neuro
Eliem Therapeutics is a biotech company developing drugs for neurological and psychiatric disorders. This chart, showing employment in the neuroscience sector, illustrates the enormous need for new treatments and the complexity of this field. For Eliem, the growing number of researchers means both accelerating science and heightened competition for breakthrough ideas.
Number of employees in the market as a whole
Eliem Therapeutics develops treatments for neurological disorders. As with any clinical-stage company, access to funding is a key factor for success. The growth in overall employment, reflected in this chart, is a sign of a strong economy, where investors are more willing to invest in long-term, capital-intensive projects in the biotech sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Eliem Therapeutics (ELYM)
Eliem Therapeutics (ELYM) is a biopharmaceutical company focused on neuroscience. This metric, for a development-stage biotech, is an indicator of concentrated value. Market value is based on expectations for clinical trials and the value of patents. A small team of scientists can create an asset worth billions, leading to a very high valuation per employee.
%20of%20the%20company%20Eliem%20Therapeutics%20(ELYM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Eliem-Therapeutics-ELYM&v=1772678949845 "Chart of market capitalization per employee (in thousands of dollars) of the company Eliem Therapeutics (ELYM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Eliem Therapeutics develops drugs for the treatment of neurological disorders. In biotech, a company's value is determined by its intellectual property and clinical trial potential. This chart shows the market premium for innovative potential per researcher.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772678949873 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Eliem Therapeutics is a clinical-stage biotech company focused on treating neurological disorders. Its market cap is based on the potential of its scientific developments. This chart for Eliem illustrates how, in research-intensive industries, the market value per employee can be very high, reflecting investor expectations for future breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772678949881 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Eliem Therapeutics (ELYM)
Eliem Therapeutics is a biotech R&D company focused on neuroscience. Like its peers in the sector, it is profitless. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20Eliem%20Therapeutics%20(ELYM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Eliem-Therapeutics-ELYM&v=1772678949892 "Company Profit Per Employee (in thousands of dollars) Chart Eliem Therapeutics (ELYM)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Eliem Therapeutics is a biotechnology company developing treatments for neurological disorders. In this complex field, the effectiveness of the research and development team is paramount. This metric demonstrates the financial return each employee brings, which is an indicator of the company's productivity in finding new therapeutic solutions.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772678949905 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Eliem Therapeutics is a biotech company focused on developing drugs to treat neurological disorders such as pain and depression. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772678949910 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Eliem Therapeutics (ELYM)
Eliem Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurological diseases. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Eliem-Therapeutics-ELYM&v=1772678949956 "Sales chart per company employee Eliem Therapeutics (ELYM)")
Sales per employee in the market segment - Neuro
Eliem Therapeutics (ELYM) is a clinical-stage biotech focused on developing treatments for neurological disorders (pain, depression). This chart shows the average revenue per employee in the sector. It is important for assessing the efficiency of capital utilization and personnel structure compared to other neuroscience biotechs.
Sales per employee for the market as a whole
Eliem Therapeutics (ELYM) is a biotech company focused on developing new treatments for neurological disorders such as pain and depression. The company is in the clinical R&D stage. This near-zero operating cost reflects the ongoing operating expenses of the research staff working on developing new drugs in this complex field.
Short shares by company, segment and market as a whole
Shares shorted by company Eliem Therapeutics (ELYM)
Eliem Therapeutics (ELYM) is a neuroscience biotech that has suffered significant setbacks in clinical trials, leading to the program's shutdown. This chart shows short interest. High short bets reflect investor bets that the company has no valuable assets left and is headed for liquidation or a reverse merger. (346)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Eliem-Therapeutics-ELYM&v=1772678950028 "Short Shares Chart for the Company Eliem Therapeutics (ELYM)")
Shares shorted by market segment - Neuro
Eliem Therapeutics (ELYM) is a biotech company developing drugs to treat neurological disorders, including pain and depression. The chart below shows the overall short position in the CNS biotech sector. It demonstrates the lack of investor confidence in the success of complex and lengthy clinical trials in this area.
Shares shorted by the overall market
Eliem is a neuroscience biotech company facing R&D setbacks. This chart illustrates the overall market pessimism. When investors are fearful, they don't forgive past failures. They see an R&D company burning through its remaining cash and sell off its shares, not believing in a "second chance."
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Eliem Therapeutics (ELYM)
Eliem Therapeutics (ELYM) is a biotech company that has suffered setbacks in developing drugs for pain and depression and is now exploring new avenues. It is a speculative asset. This oscillator measures the strength of speculative moves. It shows when brief surges of hope (above 70) or deep disappointment (below 30) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Eliem-Therapeutics-ELYM&v=1772678950116 "RSI 14 indicator chart for the company's stock Eliem Therapeutics (ELYM)")
RSI 14 Market Segment - Neuro
Eliem Therapeutics is a biotech company specializing in developing drugs to treat central nervous system disorders, such as chronic pain and depression. This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire speculative segment is oversold.
RSI 14 for the overall market
For Eliem Therapeutics, a biotech in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ELYM (Eliem Therapeutics)
Eliem Therapeutics is a biotech company that, following clinical trial failures for drugs to treat neurological conditions (pain, depression), is seeking strategic alternatives. This chart shows the speculative average price target from analysts, which primarily reflects their assessment of the company's remaining cash value.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ELYM-Eliem-Therapeutics&v=1772678950234 "A chart showing analyst consensus forecasts for the expected stock price. ELYM (Eliem Therapeutics)")
The difference between the consensus estimate and the actual stock price ELYM (Eliem Therapeutics)
Eliem Therapeutics is a biotech company focused on developing drugs for the treatment of central nervous system diseases (chronic pain, depression). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of the risks and potential of this complex R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ELYM-Eliem-Therapeutics&v=1772678950269 "A chart showing the difference between the consensus forecast and the actual stock price. ELYM (Eliem Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Eliem Therapeutics is a clinical-stage biotech company developing new drugs for the treatment of chronic pain and depression. This is high-risk R&D. This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of CNS diseases are possible.
Analysts' consensus forecast for the overall market share price
Eliem Therapeutics is a biotech company specializing in developing drugs for the treatment of central nervous system disorders (depression, pain). This chart reflects the overall market "risk appetite." For Eliem, a clinical-stage company, overall market optimism (risk appetite) is critical for attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Eliem Therapeutics
Eliem Therapeutics is a biotech R&D company focused on neuroscience (CNS). They are developing small molecules (tablets) for the treatment of chronic pain and depression. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline, their clinical trial data, and their race to keep up the good work.
AKIMA Market Segment Index - Neuro
Eliem Therapeutics is a biopharmaceutical company focused on neuroscience. They develop drugs to treat chronic pain and depression—large but complex markets. This chart compares their composite index to the sector, showing how their neuroscience R&D stacks up against their peers.
The AKIM Index for the overall market
Eliem Therapeutics is a biotech company that refocused on autoimmune diseases after merging with Tenet Medicines. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ELYM, which is relaunching its story with new assets, compares to overall economic trends.
